TY  - JOUR
AU  - Brinkmann, Berit J
AU  - Floerchinger, Alessia
AU  - Schniederjohann, Christina
AU  - Roider, Tobias
AU  - Coelho, Mariana
AU  - Mack, Norman
AU  - Bruch, Peter-Martin
AU  - Liebers, Nora
AU  - Dötsch, Sarah
AU  - Busch, Dirk H
AU  - Schmitt, Michael
AU  - Neumann, Frank
AU  - Roessner, Philipp M
AU  - Seiffert, Martina
AU  - Dietrich, Sascha
TI  - CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
JO  - Blood
VL  - 144
IS  - 7
SN  - 0006-4971
CY  - Washington, DC
PB  - American Society of Hematology
M1  - DKFZ-2024-01152
SP  - 784-789
PY  - 2024
N1  - 2024 Aug 15;144(7):784-789
AB  - Anti-CD19 chimeric antigen receptor T-cells (CD19-CAR) represent an effective treatment for relapsed/refractory B-cell malignancies but incomplete responses often result in early disease progression. We here assessed potential benefits of co-administering CD20-targeting bispecific antibodies (CD20-BsAb) with CD19-CAR, aiming to enhance immunotherapeutic efficacy. Addition of CD20-BsAb to co-cultures of CD19-CAR and primary samples of B-cell malignancies, comprising malignant B- and endogenous T-cells, significantly improved killing of malignant cells alongside enhanced expansion of both endogenous T-cells and CD19-CAR. CD20-BsAb induced an increase in proliferation and activation of endogenous T-cells and CD19-CAR. In an immunocompetent mouse model of CLL, relapse after initial treatment response frequently occurred after CD19-CAR monotherapy. Combination with injections of CD20-BsAb significantly enhanced treatment response and resulted in improved eradication of malignant cells. Higher efficacy was accompanied by improved T-cell expansion upon CD20-BsAb administration and resulted in longer survival, with 80
LB  - PUB:(DE-HGF)16
C6  - pmid:38805637
DO  - DOI:10.1182/blood.2023022682
UR  - https://inrepo02.dkfz.de/record/290535
ER  -